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LIST OF ABBREVIATIONS  
 
ATCC: American Type Culture Collection 
BP: blood pressure 
CT: cytotrophoblast  
CTR: control 
DMSO: Dimethyl sulfoxide 
ECGM: Endothelial Cell Growth Medium 
EHS: Engelbreth-Holm-Swarm (mouse sarcoma) 
EMT: epithelial-mesenchymal transition  
EVs: extracellular vesicles 
EVT: extravillous trophoblasts  
EXO: exosomes 
FBS: Fetal Bovine Serum  
GFR: Growth Factor Reduced 
H: hours 
HUVEC: Human Umbilical Vein Endothelial Cells  
ILV: intraluminal vesicles  
miRNAs: microRNAs 
ml: milliliters 
min: minutes 
MMP: matrix metalloproteinases  
MV: microvesicles 
MVB: multivesicular bodies 
NTA: nanoparticle tracking analysis 
PBS: phosphate-buffered saline  
pri-miRNAs: primary miRNAs  
pre-miRNA: precursor miRNA  
RT: room temperature 
SCR-mimic: scramble mimic 
SEM: standard error of the mean  
ST: syncytiotrophoblast 
TBS: Tris-Buffer Saline 
 
II 
TBS-T: Tween20 in TBS   
 
III 
SUMMARY 
 
Preeclampsia constitutes a hypertensive disorder exclusive to pregnancy. It is a 
systemic disease with multi-organ involvement that complicates between 2 - 8% of 
all pregnancies, remaining one of the primary causes of maternal and perinatal 
morbidity and mortality in the world. Preeclampsia has been associated with 
improper extravillous trophoblast invasion into uterine spiral arteries and deficiency 
of their remodeling. Previous studies have revealed that trophoblast cells secrete 
microRNAs (miRNAs) into the maternal circulation by packing them within 
extracellular vesicles (EVs). This process takes place in normal and in preeclamptic 
pregnancies, but at different quantities and qualities, indicating its potential role in 
physiology and pathology of the placenta. EVs are present in maternal plasma from 
early pregnancy onwards, which represents potential diagnostic tools as biomarkers 
for gestational pathologies.  
 
Previous studies in our lab showed that miR-141 expression is higher in placentas 
from preeclamptic compared to normal pregnancies. miR-141 is a pregnancy-
related miRNA known to control trophoblast functions and to be associated with the 
process of angiogenesis. The aim of this study was to further investigate the role of 
miR-141 in the vascular remodeling of endothelial cells by trophoblastic cells using 
a 3D in vitro co-culture model of Human Umbilical Vein Endothelial Cells (HUVEC) 
and trophoblastic cells (HTR8/SVneo and JEG-3 cells).  
 
The 3D co-culture model was established for quantitative evaluation of vascular 
tube-like formations as a method. When HTR8/SVneo cells were co-cultured with 
HUVEC, the tube formations were more permanent and stable, simulating the 
interaction between endothelial and trophoblast cells, and thus the remodeling of 
uterine spiral arteries in pregnancy. 
 
Trophoblastic cells were modified by transient transfection to mimic miR-141 levels 
as observed in preeclampsia. Overexpression of miR-141 in HTR8/SVneo cells 
resulted in a highly significant disruption of tube formations when co-cultured with 
HUVEC, but this effect was not evident when using JEG-3 cells. Due to the poor 
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interaction between HUVEC and JEG-3 cells, only HTR8/SVneo cells were used to 
investigate the effect of miR-141-containing EVs on the tube formation. 
 
Supernatant from miR-141-mimic transfected HTR8/SVneo cells was used to obtain 
EV-enriched fractions through differential ultracentrifugation. Subsequent 
characterization of EVs was done by using a Nanoparticle Tracking Analysis (size 
and concentration) and membrane proteins were confirmed with a Dot-Blot 
technique. Characterized EVs from transfected and control cells were added to non-
modified HTR8/SVneo cells in the 3D cell culture model. Changes in the tube 
formation were evaluated through microscopy and image analysis. This treatment 
showed a similar disruptive effect, result appreciated with the co-culture of 
transfected trophoblastic cells and HUVEC.  
 
Consequently, we can conclude that miR-141 is involved in the regulation of the 
angiogenic potential of trophoblastic cells. This regulation may be affected by 
communication between endothelial cells and miR-141-containing trophoblast-
derived EVs. These effects may be related to processes during uterine spiral 
arteries remodeling and its disorders, such as the development of preeclampsia.  
 
 
 
 
 
 
 
 
 
 
  
 
V 
ZUSAMMENFASSUNG 
 
Die Präeklampsie stellt eine hypertensive Störung ausschließlich während der 
Schwangerschaft dar. Es handelt sich um eine systemische Erkrankung mehrerer 
Organe, die  bei 2 - 8% aller Schwangerschaften auftritt. Sie ist somit eine der 
Hauptursachen für mütterliche und perinatale Morbidität und Mortalität in der Welt. 
Präeklampsie wurde mit einer gestörten extravillösen Trophoblastzellinvasion in 
den Uterusspiralarterien und einem Mangel in ihrem Umbau in Verbindung 
gebracht. Frühere Studien haben gezeigt, dass Trophoblastzellen extrazelluläre 
Vesikel (EVs) in den mütterlichen Kreislauf sezernieren, welche microRNAs 
(miRNAs) enthalten. Dieser Prozess findet in normalen und in präeklamptischen 
Schwangerschaften statt, jedoch variieren sowohl Vesikelmenge als auch deren 
Inhalt, was auf eine potentielle Rolle der EVs in der Physiologie und Pathologie der 
Plazenta hindeutet. Trophoblastäre EVs sind ab der frühen Schwangerschaft im 
mütterlichen Plasma vorhanden und haben daher das Potenzial als Biomarker für 
die Diagnose von Schwangerschaftspathologien.  
 
Frühere Studien in unserem Labor zeigten, dass die Expression von miR-141 in der 
Plazenta von präeklamptischen Schwangerschaften im Vergleich zu normalen 
Schwangerschaften höher ist. miR-141 ist eine schwangerschaftsassoziierte 
miRNA, der die Kontrolle von Trophoblastzellfunktionen zugeordnet wird, und die in 
die Regulation der Angiogenese involviert ist. Das Ziel dieser Studie war es, die 
Rolle von miR-141 beim vaskulären Umbau von Endothelzellen durch 
trophoblastären Zellen zu untersuchen. Dafür wurde ein 3D-in-vitro Co-Kulturmodell 
von Human Umbilical Vein Endothelial Cells (HUVEC) und trophoblastären Zellen 
(HTR8/SVneo- und JEG-3-Zellen) verwendet. 
 
Die 3D-in-vitro Zellkultur wurde als eine Methode etabliert, welche die extrazelluläre 
Matrix simuliert und die quantitative Analyse von Veränderungen an der räumlichen 
kapillaren Wachstumsstruktur der Zellen (Tubusbildung) ermöglicht. HTR8/SVneo-
Zellen, die in Matrigel ausgesät werden, wachsen in einem tubulären Netzwerk 
wobei sie einen endothelialen Phänotyp annehmen. Bei gleichzeitiger Kultivierung 
mit HUVEC leitet diese Eigenschaft auch die HUVEC zu einer verstärkten 
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Ausbildung von Tubusstrukturen und simuliert die Bildung der uterinen 
Spiralarterien während der Schwangerschaft. 
 
Die trophoblastären Zellen wurden durch transiente Transfektion mit miR-141 
modifiziert, um miR-141-Spiegel wie bei der Präeklampsie zu imitieren. Die 
Überexpression von miR-141 in HTR8/SVneo-Zellen führte bei deren Co-Kultur mit 
HUVEC zu einer hochsignifikanten Unterbrechung dieser Tubusbildung. Dieser 
Effekt war jedoch bei Verwendung von JEG-3-Zellen nicht erkennbar. Aufgrund der 
geringen Wechselwirkung zwischen HUVEC und JEG-3-Zellen wurden nur 
HTR8/SVneo-Zellen verwendet, um die Wirkung von EVs mit modifiziertem miR-
141-Gehalt auf die Tubusbildung zu untersuchen. 
 
Der Zellkultur-Überstand von miR-141-transfizierten Zellen wurde verwendet, um 
die EV-angereicherte Fraktionen durch differentielle Ultrazentrifugation zu erhalten. 
Die anschließende Charakterisierung erfolgte unter Verwendung der Nanopartikel-
Tracking-Analyse (Bestimmung der Größe und Konzentration der EVs) und der 
Nachweis von Membranproteinen erfolgte über eine Dot-Blot-Technik. Die 
unterschiedlichen EVs wurden dann zur 3D-Co-Kultur nicht-modifizierter 
HTR8/SVneo-Zellen mit HUVEC hinzugefügt. Änderungen in der Tubusbildung 
aufgrund der jeweiligen EV-Zugabe wurden durch Mikroskopie und Bildanalyse 
bestimmt. Die Zugabe von EVs mit erhöhten miR-141 Konzentrationen zu den Co-
Kulturen von HTR8/SVneo-Zellen und HUVEC hatte ähnliche Wirkungen auf die 
Angiogenese wie die direkte miR-141-Transfektion der HTR8/SVneo-Zellen. 
 
Daraus lässt sich schlussfolgern, dass miR-141 eine Beteiligung an der Regulation 
des angiogenen Potentials trophoblastärer Zellen hat. Es wird vermutet, dass diese 
Regulation durch die Kommunikation zwischen Trophoblastzellen und 
Endothelzellen durch miR-141-haltige EVs beeinflusst wird. Wir vermuten, dass die 
beobachteten Effekte Prozesse des gestörten vaskulären Umbaus der 
Uterusspiralarterien bei einer Präeklampsie widerspiegeln. 
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1.  INTRODUCTION 
 
During human pregnancy, the placenta allows the exchange of gasses and 
nutrients between the mother and the fetus. The maternal blood that surrounds the 
syncytiotrophoblasts in the intervillous space interacts with the fetal capillary blood 
within the connective tissue at the villous core (Wang and Zhao 2010). This 
interaction can be disrupted by an inappropriate remodeling of the uterine spiral 
arteries, causing disturbances during pregnancy, such as preeclampsia. 
 
Preeclampsia is one of the clinical syndromes that remains the primary cause of 
maternal and perinatal morbidity and mortality in the world (Powe, Levine et al. 
2011). It also occurs in molar pregnancies, indicating that it relays more on the 
placenta than in a fetal origin (Ahmed and Ramma 2015). Thus far, the only 
curative treatment for preeclampsia is termination of pregnancy. Therefore, the 
possibility to find a premature detection of this disease through biomarkers has 
been studied in the last years.    
 
Biomarkers are molecules that objectively identify, in a quantitative way, a normal or 
a pathological situation (Strimbu and Tavel 2010). In pregnancy, fetal miRNAs can 
be found in the maternal circulation from early pregnancy onward, via EVs, but at 
different quantities and qualities (Burton and Jauniaux 2015). These differences in 
content and the fact that EVs are found in maternal blood is what makes these 
particles essential for early detection of preeclampsia.    
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1.1. Implantation, Invasion, and Placentation   
 
1.1.1. Implantation  
After fertilization, the conceptus follows a series of steps leading to its implantation 
into the maternal endometrium (Imakawa, Bai et al. 2017):  
 
 Transport of the conceptus  
During the next days after fertilization, the zygote, a diploid cell with 46 
chromosomes is transported from the ampulla of the fallopian tube into the 
uterine cavity. The zygote suffers a continuous process of cell proliferation, 
without volume increase, until it becomes a solid collection of multiple cells 
surrounded by the zona pellucida, called morula. 
 
 Blastocyst formation  
Around the 4th – 6th day after fertilization, gradual accumulation of fluid between 
the cells of the morula results in the formation of the early blastocyst 
(Cunningham and Williams 2010). The inner cell mass of the blastocyst 
(embryoblast) will develop as the actual embryo, and the outer flat cells will 
compact to each other to form the trophoblast.  
 
 Embryo implantation 
In humans, the window of implantation occurs 6 – 10 days after ovulation (Su 
and Fazleabas 2015). It starts with an adhesion phase, where the embryoblast 
already emerged from the zona pellucida and adheres itself into the uterine 
epithelium, facing the endometrium, commonly in the superior and posterior 
walls of the uterine body. When the embryoblast does not face the 
endometrium, it migrates along the inside face of the trophoblast to align itself. 
The firm adhesion of the blastocyst is recognized as the attachment phase, and 
it cannot be removed, starting the process of invasion.  
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1.1.2. Trophoblast invasion and placentation 
The trophoblasts migrate into the endothelium and fuse to become the 
syncytiotrophoblast (ST). Meanwhile, the rest of the trophoblasts, now called 
cytotrophoblast (CT), surround the embryoblast and form columns. These 
structures break through the ST layer to form the primary chorionic villi and give 
rise to villous and extravillous trophoblasts (EVT). This process is considered as 
the beginning of placentation. The villous trophoblasts are responsible for the 
exchange of oxygen and nutrients between fetus and mother. By the 10th week of 
pregnancy, the EVT colonize the opening wall of the maternal uterine spiral 
arteries because of their high invasion ability (Cunningham and Williams 2010).  
 
1.1.3. Uterine spiral arteries remodeling   
 Physiological changes 
The EVT are further classified as interstitial and endovascular trophoblasts. The 
interstitial trophoblasts migrate through the endometrial stroma, penetrate the 
walls of the uterine spiral arteries from outside, and present characteristics of 
an epithelial to mesenchymal transition (EMT) (Soares, Chakraborty et al. 
2014). During EMT, important step in the invasion, the epithelial cells lose their 
apicobasal polarity and the tight cell-cell adhesion resulting in a mesenchymal 
phenotype and improved migratory abilities, by downregulation of E-cadherin 
and upregulation of Vimentin and N-cadherin (Senfter, Madlener et al. 2016). 
 
Meanwhile, the endovascular trophoblasts migrate to the lumen, modify the 
smooth muscle layer of the uterine spiral arteries by a partial replacement of the 
endothelial cells, and display an epithelial to endothelial-like transformation 
(Soares, Chakraborty et al. 2014). By accumulation, the endovascular 
trophoblasts cause an occlusion known as the spiral arteriole plug, which 
reduces the maternal blood flow leaving the embryo nourishment depending on 
the endometrial glands (Degner, Magness et al. 2017).  
 
The uterine spiral arteries suffer different changes on the cellular and 
extracellular constituents including migration, hyperplasia, apoptosis, and 
extracellular matrix remodeling. Because of the replacement of the tunica 
media, the spiral arteries lose their compression ability, changing from narrow 
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into wide conduits, with reduced resistance to blood flow. In order to keep up 
with the growing metabolic needs of the fetus, the spiral arteries often reach 
500 µm in diameter at the end of pregnancy (Degner, Magness et al. 2017). 
The blood flow increases from about 45 ml/min in the non-pregnant uterus to 
approximately 750 ml/min at term (Burton, Woods et al. 2009).  
 
 Pathological changes: improper EVT invasion  
Defective EVT invasion into the uterine spiral arteries and the resulting 
deficiency of their remodeling have been associated with preeclampsia, 
(O'Tierney-Ginn and Lash 2014). The uterine spiral arteries in preeclampsia 
remain with a mean diameter of 200 µm, similar to the size and composition as 
seen in non-pregnant women (the comparison is shown in Figure 1). Also, in 
preeclampsia, these vessels are still responsive to vasomotor stimuli, causing a 
decrease in the uteroplacental perfusion pressure and restricting the blood 
supply to the fetus (Degner, Magness et al. 2017). These alterations can lead to 
placental ischemia/hypoxia and alteration in the maternal immune response, 
leading to systemic endothelial dysfunction which appears as the common 
clinical features seen in preeclampsia.  
 
The detection of disturbances in the placental flow is possible after the 12th 
week of gestation, period of time when the maternal blood flow toward the 
placenta is established (Huppertz 2008). Although disturbances are noticed by 
ultrasonography, it is worth saying that it is not a unique characteristic of 
preeclampsia and not enough for a proper diagnosis. The establishment of a 
proper and early diagnosis will improve the antenatal and perinatal care.  
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Figure 1. Uterine spiral arteries during physiological or pathological processes.  
During normal pregnancy, uterine spiral arteries widen and often reaching 500 µm in 
diameter at the end of pregnancy. This effect is not seen in preeclampsia because of the 
poor EVT invasion, remaining with a mean diameter of 200 µm, similar size, and 
composition of the ones seen in non-pregnant women.  
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1.2. Preeclampsia  
 
1.2.1. Epidemiology 
Preeclampsia is a multisystem hypertensive disorder and one of the primary 
causes of maternal and perinatal morbidity and mortality in the world. It affects 
between 2 - 8% of all pregnancies and is responsible for 9 – 26% of the maternal 
deaths worldwide (Townsend, O'Brien et al. 2016). Its onset is multifactorial: more 
common in African-American women, low socioeconomic status, multifetal 
gestation and primigravidas (Steegers, von Dadelszen et al. 2010). Preeclampsia 
is increasing nowadays due to higher maternal age, obesity, and other medical 
comorbidities, as diabetes and hypertension; and a need for early detection and 
treatment is required to improve maternal and neonatal health (WHO 2011). 
 
1.2.2. Clinical features 
The International Society for the Study of Hypertension in Pregnancy (ISSHP) has 
re-defined preeclampsia as de-novo hypertension after 20 weeks of gestation: 
blood pressure (BP) ≥ 140 mmHg systolic or ≥ 90 mmHg diastolic, on 2 occasions 
at least 6 h apart, while the patient is on bed rest; combined with the onset of one 
or more of the following conditions (Bokslag, van Weissenbruch et al. 2016):  
a. Proteinuria, or 
b. Maternal organ dysfunction  
 renal insufficiency  
 liver involvement  
 neurological complications  
 hematological complications  
c. Uteroplacental dysfunction (fetal growth restriction) 
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1.2.3. Classifications 
 Clinical: mild vs severe 
The disease severity is based on the BP measurement and whether there are 
signs of systemic involvement (Tranquilli, Dekker et al. 2014). 
o Mild / moderate: BP 140 - 159 mmHg systolic and/or 90 - 109 mmHg 
diastolic, plus: 
 Proteinuria ≥ 300 mg/day or ≥ 2+ on dipstick testing (on 2 random 
urine samples, collected at least 4 h apart) 
 In the absence of proteinuria, any of the following: 
 Serum creatinine ≥ 1.02 mg/l  
 Elevated blood concentrations of liver transaminases to twice 
normal concentration; epigastric abdominal pain 
 Cerebral or visual disturbances: altered mental status, 
hyperreflexia, severe headaches with or without visual scotomas, 
tinnitus, phosphene signals 
 Thrombocytopenia (platelets count < 150,000/dl) 
o Severe 
 BP ≥ 160 mmHg systolic and/or ≥ 110 mmHg diastolic 
 Proteinuria 
 In the absence of proteinuria, any of the symptoms or signs mentioned 
in mild preeclampsia  
 
 Time of onset: early vs late (Huppertz 2008) 
o Early 
 Less than 34 weeks of pregnancy (34 + 0) 
 Most severe and higher rates of maternal and neonatal morbidity and 
mortality (usually, fetal growth restriction) 
 Inadequate trophoblast invasion of the uterine spiral arteries  
o Late  
 More than 34 weeks of pregnancy (34 + 1) 
 Normally grown neonate 
 Mother frequently with previous (multiples) pregnancies or/and 
pathological complications (diabetes mellitus, anemia, obesity)  
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 Etiology: placental vs maternal  
The severity and progression of preeclampsia are significantly affected by the 
maternal response to placental derived factors and proteins. Therefore, 
preeclampsia can be divided by inducement of placental or maternal factors.  
o Placental factors. This concept is based on the failure to transform the 
maternal spiral arteries, caused by the inadequate EVT invasion. This 
leads the uterine spiral arteries to remain narrow and with high pressure 
affecting the normal development of the placenta: low maternal blood flow, 
hypoperfusion, ischemia, and hypoxia of the placenta (Li, Ge et al. 2013). 
The circulation in the intervillous spaces become abnormal, damaging the 
villous branches, filling it with thrombotic material, and later detected in the 
peripheral maternal blood, causing systemic endothelial alterations 
(Burton, Woods et al. 2009). These endothelial dysfunctions cause 
microangiopathic hemolytic anemia and vascular hyperpermeability 
associated with low serum albumin inducing edema, particularly in the 
lower limbs or lungs (Uzan, Carbonnel et al. 2011). 
 
o Maternal factors. This takes place in women with previous vascular 
dysfunction exacerbated by pregnancy, such as obesity, hypertension or 
diabetes (Craici, Wagner et al. 2014). The vascular stress leads to 
damages in the endothelium and contributes to the development of 
preeclampsia (Gilani, Weissgerber et al. 2016). The maternal etiology is 
sometimes related to the late onset or with mild preeclampsia; meanwhile, 
the placental etiology is related with the early onset or with severe 
preeclampsia (Steegers, von Dadelszen et al. 2010). 
 
1.2.4. Complications  
If preeclampsia is not detected on time and treated in order to maintain maternal 
hemostasia, pregnancy condition can worsen with severe complications  
(Townsend, O'Brien et al. 2016): 
 HELLP syndrome: occurs in around 5% of mild preeclampsia or 10 – 20% of 
severe preeclampsia. It is described by Hemolysis (and consequently, 
anemia), Elevated Liver enzymes (presenting hepatic dysfunction), and Low 
Platelets (less than 150,000/dl). 
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 Eclampsia/cerebral hemorrhage: eclampsia is defined as generalized tonic-
clonic seizures that can lead to cerebral damage. Changes in the blood 
pressure can later cause hypertensive encephalopathy.  
 Renal impairment: in normal pregnancy, renal perfusion and filtration increase 
and creatinine levels should be lower than normal. During preeclampsia, the 
glomerular endothelium is directly damaged, increasing the creatinine levels.  
 Pulmonary edema: the low concentration of albumin in the blood leads to a 
reduction on the oncotic pressure and thus, a relative depletion of the 
intravascular volume with significant interstitial fluid, causing preeclamptic 
women to be vulnerable to pulmonary edema due to the significant renal 
impairment.  
 Other complications (Mol, Roberts et al. 2016) 
o Rupture of the liver  
o Myocardial ischemia or infarction 
o Disseminated intravascular coagulation  
o Placenta-related complications, such as abruption   
 
As long-term complications, affected women may suffer from stroke, cardiac 
ischemia, or venous thrombosis; and are vulnerable to a high risk of death from 
cardiovascular diseases (Gongora and Wenger 2015) (Powe, Levine et al. 2011). 
Children from mothers that suffered preeclampsia are at risk of preterm birth, fetal 
growth restriction or even fetal death (Bokslag, van Weissenbruch et al. 2016).  
 
Many difficulties remain concerning prediction of preeclampsia. In this way, the 
study of this disease through biological markers present in blood is considered 
nowadays a closer possibility. Many diseases have been studied and related to 
miRNAs, molecules that can be detected in different body fluids during normal and 
pathological situations. 
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1.3. MicroRNAs 
 
1.3.1. Description   
miRNAs are short, single-stranded, non-coding RNAs (20 - 24 nucleotides), 
involved in post-transcriptional regulation of gene expression in multicellular 
organisms by affecting the stability and translation of mRNAs. miRNAs target 
sequences in the 3’ untranslated regions (3’UTR) of the transcripts, mostly 
imperfectly, leading to mRNA degradation (Suarez and Sessa 2009). A single 
miRNA can bind and target multiple mRNAs and at the same time, one mRNA can 
be regulated by multiples miRNAs.  
 
miRNAs are initially transcribed in the nucleus by the RNA polymerase II called 
primary miRNAs (pri-miRNAs) (Ha and Kim 2014); at the 5’ end with a 5’-methyl-7-
guanosine cap and at the 3’ end, with a poly (A) tail (Gao, Feng et al. 2016). The 
nuclear microprocessor complex (composed by Drosha, a nuclear RNase III, and 
a double-stranded RNA binding protein), cleaves the pri-miRNA to release a 
hairpin-shaped precursor miRNA (pre-miRNA), which is transferred from the 
nucleus to the cytoplasm by the Exportin-5. When the pre-miRNA reaches the 
cytoplasm, it is processed by a complex containing Dicer, a specific RNase III 
endonuclease, and a double-stranded RNA-binding protein, liberating a miRNA 
duplex. The mature single-stranded form (guide strand) is incorporated into the 
RNA-induced silencing complex, repressing protein translation (Gregory and 
Shiekhattar 2005); while the complementary strand is released and typically 
degraded (Suarez and Sessa 2009). Circulating miRNAs are stable and protected 
from RNase degradation, which is achieved by their inclusion on either in various 
protein complexes or in different types of EVs (Cretoiu, Xu et al. 2016).  
 
1.3.2. miR-141 
Trophoblasts express different miRNAs that can be found in maternal blood, 
increasing throughout pregnancy and disappearing after delivery (Morales-Prieto, 
Chaiwangyen et al. 2012). The selection of the miR-141 for this project was based 
on previous studies in our lab demonstrating an importance in the regulation of 
trophoblast cells (Ospina-Prieto, Chaiwangyen et al. 2016). Furthermore, miR-141 
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is significantly higher expressed in plasma from pregnant compared to non-
pregnant women, and it is overexpressed in preeclamptic compared to normal 
placentas.   
  
miR-141 is a placenta-related miRNA, located in the gene 12p 13.31 (Li, Ge et al. 
2013). It belongs to the miR-200 family which is composed of five miRNAs: miR-
200a, -200b, -200c, -141, -429. The miR-200 family is organized into two genomic 
clusters but also into two functional groups. The clusters are located in 
chromosomes 1 (miR-200c / -200a / -429) and chromosome 12 (miR-200c and 
miR-141) (Senfter, Madlener et al. 2016). The functional groups, 1 and 2, differ by 
the third nucleotide of their sequence, either C or U, allowing some target genes to 
overlap (Pecot, Rupaimoole et al. 2013). The functional group 1 is composed by 
miR-141 and miR-200a, and the functional group 2, by miR-200b, -200c, and -429 
(Figure 2). The miR-200 family has been shown to regulate different cellular 
processes, including inhibition of the EMT by downregulation of ZEB1 and ZEB2 
(Gao, Feng et al. 2016). These genes are known to induce the expression of 
Matrix Metalloproteinases (MMP) that degrade the basement membrane, 
contributing to the trophoblast invasion (Imakawa, Bai et al. 2017).  
   
 
Figure 2. Functional groups of the miR-200 family. Both functional groups share the 
same seeding sequence from position 2 to 7 from the miRNA 5’end, but groups’ differences 
are found in the 3rd nucleotide.  
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1.4. Extracellular Vesicles  
 
Since the 2000s, EVs have shown to play an important role in the horizontal 
transfer of coding and non-coding RNA, and other molecules, allowing the 
communication between several types of eukaryotic cells (Ratajczak, Miekus et al. 
2006). This extends the idea that exosomes carry information that can be 
transferred from cell to cell either in normal conditions as well as in pathologies, 
such as preeclampsia. 
 
1.4.1. Description  
EVs are bilayer-membrane structures released from different cell types depending 
on their microenvironment. They are able to change the activity of contiguous or 
distant cells by traveling through blood circulation and releasing their content into 
the cytosol of target cells, and thus, involved in the cell-to-cell communication 
(Escudero, Herlitz et al. 2016) (Tannetta, Masliukaite et al. 2016). Aside from 
blood, EVs can also be isolated from different body fluids such as urine, 
cerebrospinal fluid, breast milk, semen, saliva and amniotic fluid.  
 
The idea of micro-particles in blood exists since a few decades ago, when Peter 
Wolf in 1967, reported the presence of “platelet-dust” after a high-speed 
centrifugation (Wolf 1967). This fraction exerted coagulation properties, while the 
supernatant did not present the same qualities. In 1983, the term “exosomes” was 
first defined by Rose M. Johnstone while mapping the trafficking of the transferrin 
receptor in the maturation of reticulocytes (Johnstone, Adam et al. 1987). They 
found the release of small membrane vesicles that were previously formed in 
intracellular endosomes, which fused with the plasma membrane and later 
secreted to the exterior. 
 
EVs are composed of different types of proteins, lipids and nucleic acids, such as 
mRNA and miRNA (Table 1). This content, protected from proteases and 
nucleases in the extracellular space, may vary depending on the biogenesis, cell 
type and surrounding conditions (Abels and Breakefield 2016).  
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Table 1. Frequent cargo of EVs, sub-classified in proteins, lipids, and nucleic acids 
Proteins 
o CD63, CD9, CD81, and other tetraspanins 
o Heparin sulfate proteoglycans 
o Integrins and immunoglobulins 
o Lectins 
Lipids 
 Phosphatidylserine 
 Sphingoglycolipids 
 Cholesterol  
Nucleic acids 
 mRNA 
 miRNA 
 other small non-coding RNA 
 
 
1.4.2. Classification 
 Exosomes (∼ 50 – 150 nm): produced through the endocytic pathway, by 
inward budding of endosomal compartments, called multivesicular bodies 
(MVB), which were formed by invagination of the cell membrane. The 
release of the exosomes into the extracellular environment is done by 
fusion of the MVB with the plasma membrane (Tannetta, Masliukaite et 
al. 2016). For years, it was described that exosomes had a cup-shaped 
appearance when seen through transmission electron microscopy; but, 
when observed by Cryo-Electron Microscopy, exosomes present a 
rounded shape, evidencing that their early descriptions contained 
artifacts of the fixation/contrast step, which induced shrinking of 
subcellular structures (Colombo, Raposo et al. 2014). Exosomes contain 
endosomal membrane markers (Tetraspanins: CD63, CD9, CD81, 
TSG101, and Alix) (Escudero, Herlitz et al. 2016); RNA species (miRNA, 
other non-coding RNA, and coding RNA); and are highly enriched in 
glycosphingolipids, cholesterol, and phosphatidylserine.  
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 Microvesicles (∼ 100 – 1,000 nm): released directly from the plasma 
membrane to the extracellular space by its outward blebbing (Tannetta, 
Masliukaite et al. 2016). Their lipid composition is similar to the plasma 
membrane, occurring selectively in the lipid-rich microdomains of the 
membrane. They are also enriched with CD40, MMP2 and CK18 protein 
markers (Escudero, Herlitz et al. 2016).  
 
 Apoptotic bodies (∼ 200 – 5,000 nm): origin from cells undergoing 
programmed death (Tannetta, Masliukaite et al. 2016). Studies in 
apoptotic bodies indicate that they are enriched in histones and 
fragmented DNA, and also contain cellular organelles and cytosolic 
components (Escudero, Herlitz et al. 2016). 
 
Table 2. Classification of EVs based on their biogenesis 
 
Size 
(nm) 
Biogenesis 
Membrane 
Markers 
(most common) 
Exosomes 50 – 150 
Endocytic 
pathway 
 
CD63 
CD81 
CD9 
Microvesicles 100 – 1,000 
Directly from the 
plasma membrane 
 
CD40 
MMP2 
CK18 
Apoptotic Bodies 200 – 5,000 
Cell fragmentation 
 
- 
 
 
15 
1.4.3. Experimental modification of miRNA content in EVs 
 
The analysis of the composition of EVs has been done to demonstrate that they are 
an actively released particle of the cell, rather than debris. Some techniques, like 
proteomic analysis, showed that their production and secretion depend on specific 
stimuli but do not occur randomly (Thery 2011). The expression of nucleic acids in 
EVs indicates their involvement in cell-cell communication. Generally, EVs are 
enriched mostly with small RNAs, characterized by multiple techniques, being 
qPCR one of them (Abels and Breakefield 2016). It has been shown that MV- and 
EXO-enriched fractions from miR-141-mimic transfected cells expressed elevated 
miR-141 levels when compared with their respective controls (Ospina-Prieto, 
Chaiwangyen et al. 2016) (Figure 3).  
 
 
Figure 3. miR-141 expression in particles isolated from the supernatant of 
trophoblastic cells. Analysis by qPCR of miR-141-containing EVs isolated from 
transfected cells shows higher expression when compared with their respective controls. 
Taken from (Ospina-Prieto, Chaiwangyen et al. 2016).  
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2.  HYPOTHESIS AND OBJECTIVES 
2.1. Hypothesis 
miR-141 is up-regulated in preeclampsia and controls viability and invasion of 
trophoblast cells. It belongs to the family of miR-200, which has been associated 
with angiogenesis in other cellular models. Because improper trophoblast ability 
to remodel HUVEC has been reported in preeclampsia, it is to hypothesize that 
miR-141 plays an important role in the vascular tube-like formations by 
regulating trophoblast-endothelial cell interaction. Likewise, secretion of miR-141 
in EVs may be involved in the angiogenesis dysregulation observed in 
preeclampsia. 
 
2.2. Objectives 
2.2.1. General 
To investigate the function of miR-141 on the trophoblast-endothelial cell 
interaction in a 3D model that resembles angiogenesis in normal and 
preeclamptic pregnancies.  
 
2.2.2. Specific  
 To establish a 3D co-culture model that allows quantification of trophoblast 
(HTR8/SVneo and JEG-3) and endothelial (HUVEC) cell interaction. 
 
 To modify the levels of miR-141 expression in trophoblastic cells and to 
investigate its effects in co-culture with HUVEC.  
 
 To isolate and characterize EVs containing elevated miR-141 levels. 
 
 To investigate the effect of miR-141-containing EVs on the endothelial tube 
formation.  
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3.  MATERIALS AND METHODS 
3.1.  Cell Lines  
3.1.1. HTR8/SVneo 
This cell line was kindly provided by C. H. Graham; Kingston, Canada. 
HTR8/SVneo cells were derived from human first-trimester trophoblast cells, 
which were immortalized by transfection with a plasmid containing the gene 
for the simian virus 40 large T antigen. These cells retain many of the 
phenotypic features of the parental cells and provide a model of placental 
functions (Graham, Hawley et al. 1993).   
 
3.1.2. JEG-3 
(DSMZ, Braunschweig, Germany); JEG-3 cells are an adherent human 
choriocarcinoma cell line, originally established by Kohler and Bridson, that 
preserves several third-trimester trophoblast-like capacities (Kohler and 
Bridson 1971). Both, the JEG-3 and the HTR8/SVneo cells, are frequently 
used as models of physiologically invasive EVT (Salomon, Yee et al. 2014). 
 
3.1.3. HUVEC 
(DMSZ, Germany); HUVEC are isolated cells from the vein of the umbilical 
cord, and are considered 'primary' cells because they have been preserved 
after only 1 to 3 passages from the initial source material (ATCC), and 
maintained in culture for experiments until passage 10. They are commonly 
used as a cell model system for the study of various physiological and 
pathological processes involving endothelial cells.   
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Figure 4. Cell lines in monolayer culture. (a) HTR8/SVneo cells (b) JEG-3 cells (c) 
HUVEC. Red line indicates 10 µm.  
 
3.2. Cell Culture Conditions 
Cells were seeded at 106 cells in 75 cm2 flasks and maintained under standard 
culture conditions: 37 °C and humidified under an atmosphere of 5% CO2-balanced 
N2 to obtain 8% O2 (pO2 ~ 54 mmHg). JEG-3 cells were cultured in Ham’s F-12 
Nutrient Mix (Gibco®, Paisley, UK) and HTR8/SVneo cells in RPMI 1640 Medium 
(Gibco®), both mediums supplemented with 10% Fetal Bovine Serum (FBS; Sigma-
Aldrich, Germany) and 1% Penicillin-Streptomycin antibiotic solution (Gibco®). 
HUVEC were seeded in Endothelial Cell Growth Medium (ECGM; PromoCell, 
Heidelberg, Germany) supplemented with 10% FBS and Supplement Mix 
(PromoCell). All cell lines were routinely tested to confirm the absence of 
Mycoplasma. 
 
3.3.  Transfection  
Trophoblastic cells were cultured in 6-well plates and allowed to attach overnight, 
and used after reaching 40 – 60% of confluence. To overexpress miR-141, cells 
were transfected with miR-141-mimic (mirVana® miRNA mimic, Ambion). To 
suppress native miR-141 expression, JEG-3 cells were transfected with miR-141 
inhibitor (ThermoScientific, Dharmacon). In order to assess the specificity of the 
transfection with miR-141-mimic or –inhibitor, cells were transfected with non-
genomic scrambled sequences, labeled respectively as SCR-mimic (mirVanaTM 
miRNA mimic negative control #1; Ambion) and –inhibitor (mirVanaTM miRNA 
inhibitor negative control #1; Ambion). All the sequences were transfected at a final 
concentration of 25 nM using oligofectamine transfection reagent (OligofectamineTM 
Reagent, Invitrogen, California, USA) according to the manufacturer’s 
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recommendations. Cells were seeded in reduced serum media OPTI-MEM® I + 
GlutaMAXTM –I (Gibco®) and 4 h after incubation with sequences, medium 
containing 30% FBS Exosome-Depleted (Gibco®) was added and left overnight. To 
minimize toxicity, the used medium was replaced at the next day with 5 ml of 
medium containing 10% FBS Exosome-Depleted. 
 
3.4. Tube Formation Assay 
3.4.1. Initial protocol 
Day 1  
Corning® Matrigel® Basement Membrane Matrix Growth Factor Reduced (GFR; 
Corning, Bedford, MA, USA) is a solubilized basement membrane preparation 
extracted from the Engelbreth-Holm-Swarm (EHS) mouse sarcoma, a tumor rich in 
extracellular matrix proteins. It was previously thawed (from −20 °C) by leaving it 
overnight at 4 °C and kept on ice because it gels above 10 °C. CultureSlides (BD 
Falcon, NY, USA) and pipettes tips were pre-cooled at -20 °C. CultureSlides were 
coated with 250 µl Matrigel, avoiding air bubbles, and incubated at 37 °C for 30 min 
to allow solidification. The wells were later filled up with 1 ml of supplemented 
ECGM and incubated at 37 °C overnight.  
 
Day 2 
Staining was done using CellTracker™ Green CMFDA Dye (Life Technologies, OR, 
USA), beforehand dissolved in Dimethyl Sulfoxide (DMSO) to a final concentration 
of 10 mM. The stock solution was diluted in serum-free medium to obtain a working 
solution of 10 µM. This working solution was added to 5 x 105 HUVEC in a 25 cm2 
flask and incubated for 30 min at 37 °C. CellTracker™ solution was then removed; 
cells were washed three times with phosphate-buffered saline (PBS), detached with 
Trypsin/EDTA and seeded on Matrigel-coated CultureSlides (100,000 cells/ml of 
new supplemented medium). Cells in CultureSlides were incubated overnight at 37 
°C for tube formation.  
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Day 3 
Used ECGM was removed, cells were washed with PBS, and 500 µl of 
supplemented ECGM was added. Transfected trophoblastic cells were stained with 
CellTracker™ Orange CMTMR Dye (Life Technologies, OR, USA) diluted in their 
corresponding serum-free medium, using the same procedure as for HUVEC. 
100,000 stained cells in 500 µL of the corresponding supplemented medium were 
added to the CultureSlides, having a total of 1 ml combined medium in the 
CultureSlides. 
 
Day 4 
After removing medium from CultureSlides, cells were washed carefully with PBS 
and fixed by adding 1 ml of Methanol/DMSO (4:1) for 24 h at 4 °C.  
 
Day 5 
Methanol/DMSO was removed; chamber washed with PBS, and plastic cover from 
the chambers was detached. VectaShield® (Vector Laboratories, CA, USA), a 
mounting medium for fluorescence was added. A coverslip was carefully placed 
over the slides and sealed with nail polish to avoid detachment of the coverslip. 
Changes in the tube formation were observed and images were taken at low 
magnification (50x) using an Olympus IX-81 inverted system microscope (Olympus 
Europe Holding, Hamburg, Germany).  
 
 
Figure 5. Experimental design for the tube formation assay in CultureSlides.  
Preparation and culture in a 5-day experiment, summarizing the steps day by day.  
 
This initial protocol had several disadvantages, such as the high number of HUVEC 
required, their short lifespan in culture, and the amount of Matrigel (250 µl per 
chamber, 6 chambers) per experiment. Therefore, part of this study was to improve 
this method to reduce experimentation time and costs.  
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3.4.2. Optimized protocol 
Day 1 
Corning® Matrigel® Basement Membrane Matrix GFR Phenol Red Free (Corning, 
Bedford, MA, USA) was thawed from −20 °C by leaving it overnight at 4 °C and kept 
on ice. μ–Plate Angiogenesis 96Well, ibiTreat (ibidi, Munich, Germany) were coated 
with 10 µl Matrigel, avoiding air bubbles, and incubated at 37 °C for 30 min to allow 
solidification. Thereafter, wells were filled up with 50 µl supplemented ECGM and 
incubated overnight.   
 
Day 2  
5 x 105 HUVEC in a 25 cm2 flask were stained for 30 min at 37 °C with 
CellTracker™ Green CMFDA dye (Excitation 492 nm, Emission 517nm) diluted in 
serum-free ECGM at a final concentration of 10 µM. After CellTracker™ solution 
was removed; cells were washed, seeded at 6,500 cells per well and incubated at 
37 °C for at least 4 h for tube formation. During that time, trophoblastic cells were 
stained with CellTracker™ Orange CMTMR (Ex. 540 nm, Em. 565 nm) dye diluted 
in their corresponding serum-free medium, using the same procedure as with 
HUVEC. Trophoblastic cells were seeded on the HUVEC tube formation trying not 
to touch the gel matrix with the pipet tip. Excitation and emission values referred 
above as the absorption and fluorescence emission maxima of the respective 
fluorescent dyes.  
 
Day 3 
After 20 h of co-culture, changes in the tube formation were observed and pictures 
were taken at low magnification (50x) using an Olympus IX-81 inverted system 
microscope. Fixation was not needed. Each tube formation assay was performed in 
at least three independent experiments using minimum three Matrigel-coated wells 
per condition and one picture per well, with each filter, FITC and TRITC, and the 
merge of both images. FITC filter for the green fluorescent dye applied to HUVEC 
(Ex. 463 – 500 nm, Em. 516 – 556 nm) and TRITC filter for the red fluorescent dye 
applied to trophoblastic cells (Ex. 532 – 544 nm, Em. 573 - 613 nm).  
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Figure 6. Experimental design for the tube formation assay in μ–Plate Angiogenesis 
96Well. a) HUVEC were stained with a green fluorescent dye (Cell Tracker Green) and 
later seeded on Matrigel. b) Trophoblastic cells were stained with an orange fluorescent 
dye (Cell Tracker Orange) and co-cultured with HUVEC, which after 4 h presented vascular 
tube-like formations on Matrigel. c) After 24 h of co-culture incubation, image 
documentation was done with an inverted fluorescence microscope.  
 
3.5.  ImageJ Analysis  
The tube formation assay was evaluated using the Angiogenesis Analyzer plugin 
developed by Carpentier (Gilles Carpentier. Contribution: Angiogenesis Analyzer. 
ImageJ News, 5 October 2012), implemented in the software ImageJ from the 
National Institutes of Health, Maryland, USA. Both, the Angiogenesis Analyzer 
plugin and ImageJ are free downloadable data processing programs that quantify 
different parameters such as the length of tubes, segments, and nodes (branching 
points), appreciated in different colors on the final network analysis (c, Figure 7). 
The pictures from the merged filters were used for the analysis because they 
showed better the interaction between both cells types. Before analysis, images 
were changed to an 8-bit format and then to a binary tree format (b, Figure 7). Mean 
numbers of nodes between tubes were calculated, defining a node as the single 
point formation when at least three cells are connected (seen in red in (c), Figure 7).  
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Figure 7. ImageJ Angiogenesis Analyzer. (a) Original merged image, HUVEC (green) 
and HTR8/SVneo cells (red). (b) Binary Tree. (c) Network Analysis. Red points: nodes, 
green: branches, yellow: master segments, blue: isolated elements.   
 
3.6.  Extracellular Vesicle Isolation  
The isolation of enriched-EV fractions (MVs and EXOs) was performed using 
consecutive centrifugation steps as published by Thery et al. (Thery, Amigorena et 
al. 2006) (Diagram as Figure 8). Five ml of the conditioned medium was collected 
24 h after transfection and centrifuged for 10 min at 380 x g to remove cellular 
debris. The supernatant was changed to a new tube (Ultra Clear Centrifuge Tubes, 
Beckman Coulter, California, USA) and ultracentrifuged for 10 min at 10,000 x g to 
remove apoptotic bodies. The supernatant was removed, placed into a new tube, 
and ultracentrifuged at 18,890 x g for 30 min. These pellets were washed in PBS, 
ultracentrifuged again at 18,890 x g for 30 min, and resuspended in 150 µl of PBS 
to obtain a MV-enriched pellet. Meanwhile, the supernatant was filtrated through 
0.8/0.2 µm pore-size filters (Acrodisc® Syringe Filters with Supor® Membrane, 
Cornwall, UK) and ultra-centrifuged at 100,000 x g for 70 min. The supernatant was 
removed; the pellet was washed with PBS and ultracentrifuged again at 100,000 x g 
for 70 min to obtain the exosome-enriched fraction. Pellets were resuspended in 
150 µl of PBS. Both pellets (EXO and MV) were stored at -80 °C until further 
analysis.  
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Figure 8. Experimental design for EVs isolation. EXO- and MV-enriched fractions 
obtained by consecutive centrifugation steps.  
 
3.7. Nanoparticle Tracking Analysis (NTA) 
For size distribution and quantification, the EV-enriched fractions were analyzed 
using NTA with a NanoSight LM10 software version 2.3 (NanoSight Ltd., Amesbury, 
UK). The NTA instrument consists of a laser beam that illuminates particles in 
suspension, a microscope connected to a camera, a hydraulic pump and a 
measuring chamber (Szatanek, Baj-Krzyworzeka et al. 2017). The light scattered by 
each particle is focused by the microscope into the camera, which identifies them 
individually, being tracked and recorded over a certain period of time (Malloy 2011) 
(Figure 9). Based on their Brownian motion, the software calculates the size and 
number of particles (Gardiner, Ferreira et al. 2013). The isolated EVs were diluted 
1:10 in PBS before analysis, and introduced into the sample chamber at room 
temperature (RT; 22.7 ± 0.23° C) using 1 ml syringes, washing the chamber with 
PBS between samples. It was recorded, for each sample, a thirty-seconds video 
and analyzed using optimized instrument settings (detection threshold: 10; settings 
 
25 
were optimized and kept constant between samples). Values were expressed as 
means of 3 isolated populations.  
 
 
Figure 9. Nanoparticle Tracking Analysis. The laser beam illuminates the particles in 
suspension, and the scattered light is focused by the microscope into the camera that 
tracks each particle based on their Brownian motion. 
 
3.8. Dot-Blot  
A nitrocellulose membrane was prepared according to the number of samples. 1µl 
of each sample was dotted into the membrane and left until dry and blotting was 
repeated for 3 more times. Previously prepared Tris-Buffer Saline (TBS) mixed with 
0.05% Tween20 (TBS-T) was used to prepare blocking solutions in combination 
with free-fat milk. TBS-T 5% milk for 30 min at RT was used to immerse the 
nitrocellulose membrane and block non-specific sites. The primary antibody anti-
human CD63 (ImmunoTools, Germany), in a dilution of 1:500 (in TBS-T 1% milk) 
was incubated with the membrane at RT for 3 h. The membrane was later washed 
with TBS-T three times, once for 10 min, and twice for 5 min. The secondary 
antibody (anti-mouse) conjugated with HRP (Cell Signaling Technology) in a dilution 
of 1:5,000 (in TBS-T 1% milk) was incubated with the membrane at RT for 1 h. The 
membrane was later washed with TBS-T three times, 5 min each, and with TBS 
once for 10 min. Incubation of the membrane was done with 500 µl of LuminataTM 
 
26 
Forte Western HRP Substrate (Millipore; MA, USA) and acquisition of the digital 
image was done on the ChemiBIS gel documentation system, with different times of 
exposure (1, 5, 10 and 15 minutes). 
 
3.9. Co-Incubation of Non-Transfected Trophoblastic 
Cells with Isolated EVs  
μ–Plate Angiogenesis 96Well were coated with 10 µl Matrigel. HUVEC were stained 
with 10 µM CellTracker™ Green CMFDA Dye and non-transfected HTR8/SVneo 
cells, with CellTracker™ Orange CMTMR Dye in the same procedure as detailed in 
the tube formation assay method (modified protocol, Figure 6). EVs from cells 
transfected with miR-141-mimic or controls were added at a concentration of 100 
µl/ml. After 18 - 20 h of co-culture incubation at 37 °C and 5% CO2, changes in the 
tube formation were observed and pictures were taken at 50x magnification using 
Olympus IX-81. Each tube formation assay was performed as three independent 
experiments using at least two wells per condition, with the two different groups of 
EVs population (EXO and MV).  
 
3.10. Statistical Analysis 
Data are expressed as mean ± standard error of the mean (SEM), performed using 
a commercially available package (Prism 6, GraphPad Inc, CA, USA). Statistical 
significance (p < 0.001) of miR-141 effects in HTR8/SVneo cells was determined 
using one-way ANOVA with Turkey correction. Statistical significance of miR-141 
effect in JEG-3 cells, comparison of the mean size and concentration of EVs, and 
analysis of EVs containing miR-141 (p < 0.05) was determined using two-way 
ANOVA with Turkey multiple comparison test. 
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4.  RESULTS  
4.1.  Experimental Design of Angiogenesis Assays  
Experiments were done according to protocols previously established in our 
laboratory. For each experiment, slides with 4 culture chambers were used. Three 
different conditions and their respective duplicates were established: non-modified 
cells as a control (CTR), non-genomic scrambled sequences (SCR-mimic and –
inhibitor, with JEG-3) and miR-141-mimic and -inhibitor. Images were taken from 
four different fields per chamber, excluding extreme edges due to gel meniscus 
formation. Initial pictures have shown a not evaluable merge of colors. Therefore, 
there were done changes on the initial protocol. The conventional Matrigel GFR 
was changed to a Phenol-Free Matrigel GFR, reducing possible interference with 
the fluorescent staining on cells. A “μ–Plate Angiogenesis 96Well”, from Ibidi, was 
applied. The bottom of each well provides an internal flat well for a 10 µl volume of 
Matrigel and a total medium volume of 50 µl per well. Taking pictures did not further 
need fixation; as a result, experiments were limited to 3 days. With these changes, 
clearer images were obtained compared to the initial protocol (Figure 10).   
 
Consequently, the reduction of the seeding area led to changes in the number of 
cells. For HUVEC, less than 5,000 cells resulted in incomplete or definitely no tube 
formations; and 10,000 cells led to overlapping formations, deciding the amount of 
6,500 cells of each cell line, per well. 
 
It was also seen that by applying the initial protocol, HUVEC died within 48 h in 
Matrigel (Figure 11). Therefore, culture-steps were also modified. It has been 
reported that, depending on the cell type, the peak of tube formation may occur 
between 3 and 12 h, tubes begin to deteriorate within 18 h and endothelial cells 
undergo apoptosis (DeCicco-Skinner, Henry et al. 2014). HUVEC formed tubes in 
Matrigel 4 h after seeding, time taken to start co-culture with trophoblastic cells. 
After 24 h of co-culture incubation, image documentation was done with an inverted 
fluorescence microscope.  
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Figure 10. Comparison between CultureSlides and μ–Plate Angiogenesis 96Well. The 
different cell lines were better distinguished between them by using the 96 well plates when 
compared with the culture slides. In the 96 well plates, HUVEC are shown in green and 
HTR8/SVneo cells in orange. 
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Figure 11. Tube formations after 24 and 48 h of HUVEC in Matrigel. a) HTR8/SVneo 
cells (orange) were seeded after 24 h HUVEC (green) incubation. The picture was taken 
after 6 h of co-culture. b) HUVEC after 48 h in Matrigel showed apoptotic cells.  
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4.2.  Cell Lines and Matrigel  
Cell growth in Matrigel differs between cell lines. HUVEC formed tubes within 4 h 
after culture in Matrigel. There was no tube formation in culture of JEG-3 cells. 
HTR8/SVneo cells showed different results: in some experiments, they tended to 
organize themselves in small groups, but in other experiments, they displayed a 
tube formation, as seen in Figure 12. This showed that HTR8/SVneo cells display 
an “endothelial-like” formation when seeded in Matrigel, which may take relevance 
in further experiments.  
 
 
Figure 12. Cell lines cultured in Matrigel. HUVEC’s usual tube formations; JEG-3 cells 
never showed this organization. In contrast, HTR8/SVneo cells have the faculty of forming 
tubes, but not seen in every experiment.  
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4.3.  Endothelial and Trophoblastic Cell Interaction  
HUVEC seeded in Matrigel have been co-cultured with two different trophoblastic 
cells: HTR8/SVneo cells, immortalized cells deriving from first-trimester trophoblast 
cells, and JEG-3 choriocarcinoma derived cells with trophoblast-like abilities. 
HTR8/SVneo cells co-cultured migrated towards the tube formations previously 
formed by HUVEC and seemed to grow in between the endothelial cells. This 
interaction remained even when the endothelial cells were apoptotic, which 
occurred after keeping the co-culture for more than 48 h, representatively seen in 
Figure 11. On the other hand, JEG-3 cells interacted poorly with HUVEC, tending to 
grow over the endothelial formations as filling up space rather than a “replacement” 
(Figure 13 and 14).  
 
 
Figure 13. HUVEC co-cultured with different trophoblastic cells. HTR8/SVneo cells 
seemed to grow in between the endothelial cells in contrast to JEG-3 cells that tend to grow 
over the endothelial tube formations. FITC, filter used for green-stained HUVEC. TRITC, 
filter used for red-stained HTR8/SVneo or JEG-3 cells. Merge defined as the combination of 
both images. 
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Figure 14. HUVEC and HTR8/SVneo cells interaction. HUVEC were stained with Cell 
Tracker Green, HTR8/SVneo cells with Cell Tracker Orange. Both cell lines were seeded in 
Matrigel and picture was taken after 24 h of co-culture, using an Olympus IX-81 at 100x.  
 
 
4.4. miR-141 Decreases HUVEC-HTR8/SVneo Interaction  
The potential influence of miR-141 on the interaction between HUVEC and 
trophoblastic cells was studied upon modification of its expression in HTR8/SVneo 
and JEG-3 cells. 20 h after transfection with miR-141-mimic, in HTR8/SVneo cells, 
a highly significant reduction (p < 0.001) of the number of nodes was detectable in 
comparison to the respective controls transfected with a non-genomic sequence 
(Figure 15). 
 
In JEG-3 cells, neither overexpression nor inhibition of miR-141 induced a 
remarkable disruption of the tube formation. The software-driven analysis of nodes 
presented a slight reduction in the number of nodes, but the differences are not 
easily distinguishable by eye (Figure 16).  
 
33 
 
Figure 15. Interaction between HUVEC and transfected HTR8/SVneo cells, and their 
respective controls. A highly significant reduction (*** p < 0.001) of the number of nodes 
was seen upon overexpression of miR-141. Bars show the mean number of nodes per well 
normalized to controls (n = 4 experiments based on independent transfections). Error bars 
show standard error. 
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Figure 16. Interaction between HUVEC and transfected JEG-3 cells (overexpression 
and inhibition of miR-141), and their respective controls. Neither overexpression nor 
inhibition of miR-141 induced a remarkable disruption of the nodes. Bars show the mean 
number of nodes per well normalized to controls (n = 3 experiments based on independent 
transfections). Error bars show standard error.  
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4.5. Effects of EVs from miR-141-overexpressed Cells on 
Non-Transfected Cells  
 
4.5.1. Nanosight  
After isolation of EVs, an evaluation of their concentration and size of each sample 
was done by using a NTA system. This method is not highly confident because the 
size of the particles can be disturbed by the surrounding medium, and because 
ultracentrifugation only enriches but does not purify them. This means that there 
may be no complete elimination of larger particles from the resulting sample. 
Nonetheless, the mean sizes of the enriched fractions, EXO and MV, were near to 
the expected as seen in Table 3 and Figure 17.   
 
 
Table 3. Comparison of the mean size of EXO- and MV-enriched fractions produced 
by HTR8/SVneo cells as assessed by NTA. (n = 3 experiments based on independent 
transfections). Data are expressed as mean ± SEM. 
 Size (nm) 
EXO 157.1 ± 28.0 
MV 258.3 ± 60.2 
 
 
 
Figure 17. Representative NTA graph for the size distribution of EXO- and MV-
enriched fractions. EVs isolated from HTR8/SVneo cell supernatants were analyzed using 
a NanoSight LM10 instrument. The curve shows the relative concentration depending on 
size.  
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The mean concentration of the EXO-enriched fraction obtained from HTR8/SVneo 
cells transfected with miR-141-mimic was slightly increased compared with their 
respective controls. Meanwhile, the mean concentration of the MV-enriched 
fraction slightly decreased compared with their respective controls (Table 4 and 
Figure 18).  
 
Table 4. Mean concentration of EVs obtained from HTR8/SVneo cells transfected with 
miR-141-mimic. (n = 3 experiments based on independent transfections). Data are 
expressed as mean ± SEM. 
         Particles x 106/ml 
CTR 
EXO   122.2 ±  21.7 
MV 180.0 ± 113.0 
SCR-mimic 
EXO 138.3 ±  21.7 
MV 156.7 ±  92.2 
miR-141-mimic 
EXO 161.1 ±  57.0 
MV 105.6 ±  29.9 
 
 
 
Figure 18. miR-141 and EVs concentration. Bars show the mean concentration of 
particles (EXO and MV) obtained from HTR8/SVneo cells transfected with miR-141-mimic. 
(n = 3 experiments based on independent transfections). Error bars show standard error. 
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4.5.2. Dot-Blot 
Dot Blot is a technique similar to the Western Blot, based to detect proteins but 
without electrophoretic separation. Because of the small amount of each sample 
obtained after enrichment through ultracentrifugation, it was taken the decision of 
using this technique as part of the EV characterization. 4µl per sample showed the 
presence or not of the protein searched, in this case, the tetraspanin CD63, 
commonly present on EXOs. Positive signals are found in human platelet and 
whole cell lysates, used as positive controls. The results showed the presence of 
the CD63 in cell lysates and blood serum (which contain platelets), and also in the 
EXO-enriched samples (Figure 19).  
 
Figure 19. CD63 presence in EXO- and MV-enriched fractions evaluated through Dot-
Blot technique. EV-enriched samples were used to observe the presence of CD63 which 
is found on human cellular membranes and also on exosomes.  
 
4.5.3. Tube formation  
After assessment of the mean concentration of EVs in each sample, it was 
decided to use a concentration of 100 µl of EVs suspension per 1 ml of culture 
medium (the equivalent to 10% of the total medium) to study their effects on the 
tube formations. HUVEC were co-cultured with non-transfected HTR8/SVneo 
cells, supplemented with MVs or EXOs, obtained from previously treated cells. 
The tube formation was evaluated by fluorescence microscopy after 20 h of co-
culture. Samples supplemented with EXO showed a significant (* p < 0.05) 
decrease of nodes, almost simulating the effect seen when transfected 
HTR8/SVneo cells were used. Co-cultures incubated with MV showed a slight, but 
not significant reduction of nodes (Figure 20).  
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Figure 20. HUVEC co-cultured with non-treated HTR8/SVneo cells and supplemented 
with EVs from previously transfected HTR8/SVneo cells. Bars show the mean number of 
nodes per well normalized to control (n = 3 experiments based on independent 
transfections). Error bars show standard error (* p < 0.05). 
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5.  DISCUSSION 
 
5.1. From Physiological Development to a Multisystemic 
Syndrome 
Preeclampsia is a hypertensive disorder diagnosed with the appearance of de-novo 
hypertension and proteinuria. These clinical signs usually appear during the second 
half of pregnancy, but initial pathogenic mechanisms, which still remain vague, arise 
much earlier. The lack of evidence about the definitive etiology and the absence of 
an adequate treatment lead to the increase in maternal and perinatal morbidity and 
mortality rates around the world (WHO 2011). So far is known, the placenta plays 
an important role in preeclampsia as the symptoms disappear after delivery. It is 
also recognized that the clinical symptoms are caused by a dysfunction of the 
maternal endothelium, a deficient trophoblast invasion and an inadequate 
remodeling of the uterine spiral arteries (Ahmed and Ramma 2015). These changes 
fall into the inadequate supply of blood to the developing uteroplacental unit, 
increasing the risk of fetal growth restrictions or unsuccessful pregnancy outcome 
caused by endothelial dysfunction (Uzan, Carbonnel et al. 2011).    
 
During the first trimester of pregnancy, the endothelial cells go through 
differentiation in the later stages of angiogenesis, a process that involves the 
formation of new blood vessels from previous vascular formations. The endothelial 
cells degrade the basement membrane, migrate toward an angiogenic stimulus, 
proliferate and organize themselves in tubular networks (Marquez-Curtis, Sultani et 
al. 2016). In vitro, these tubular networks are studied on a 3D cell culture model 
based on the patent US 20110059904 A1: Serum-based, diagnostic, biological 
assay to predict pregnancy disorders (Sharma and Kalkunte 2011), that simulates 
the interaction of fetal trophoblast cells with endothelial cells in response to 
pregnancy serum. It is grounded on the “cross-talk” between fetal and maternal 
cells at the fetal-maternal interface and the remodeling of the uterine spiral arteries 
during trophoblast invasion (Humphries and Yang 2015) (Whitley and Cartwright 
2010).  
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This 3D model uses a Matrigel basement membrane extracted from the EHS 
mouse sarcoma, a tumor rich in extracellular matrix proteins such as laminin, 
collagen IV, and heparin sulfate proteoglycans (Kleinman, McGarvey et al. 1982). 
This Matrigel simulates the extracellular matrix, but with small amounts of growth 
factors that occur naturally in the EHS tumor such as the epidermal, insulin-like, 
fibroblast and transforming growth factors, and tissue plasminogen activator 
(Guidelines for use – Corning ® Matrigel ® Basement Membrane Matrix GFR). By 
using a Matrigel GFR, stimuli interferences are reduced, and experimental settings 
are easier to define (DeCicco-Skinner, Henry et al. 2014).  
 
Cell lines frequently used as models of invasive EVT are the immortalized 
HTR8/SVneo cells that derive from human first-trimester trophoblast cells; and JEG-
3 cells, which derive from human choriocarcinoma. Although JEG-3 cells preserve 
several trophoblast-like capacities, their invasion ability is lower compared to 
HTR8/SVneo cells (Morales-Prieto, Schleussner et al. 2011) (Suman and Gupta 
2012).   
 
HUVEC seeded on Matrigel do not proliferate, but they tend to form tubular 
formations with an inner lumen (Sokolov, Lvova et al. 2017). HTR8/SVneo cells also 
create tubes in Matrigel (Highet, Zhang et al. 2012); meanwhile, JEG-3 cells do not 
show this characteristic. The reason why JEG-3 cells do not have similar capacities 
in the 3D Matrigel model is not clear. It might be that, due to their malign origin, 
JEG-3 cells present a less organized growth pattern. It can also be related to 
different genotype and the phenotype of both trophoblastic cells (Bilban, Tauber et 
al. 2010).  
 
When seeded in co-culture with HUVEC, HTR8/SVneo cells seemed to reinforce 
the endothelial tube formations rather than to form further tubes. It has been seen 
that HTR8/SVneo cells follow the original endothelial tubes, even though HUVEC 
died within the first 24 h (Aldo, Krikun et al. 2007) (Alvarez, Mulla et al. 2015). In 
vivo, trophoblast cells migrate across the endothelium, adopt an endothelial-like 
phenotype and coat the lumen within the spiral arteries by replacement of the 
endothelial cells, which undergo apoptosis (Degner, Magness et al. 2017). In vitro, 
Matrigel induces the HTR8/SVneo cells to differentiate into an invasive EVT 
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phenotype, and to create vascular tube-like formations by overexpression of CDH5, 
a gene that encodes the Vascular Endothelial Cadherin, also known as VE-cadherin 
(Highet, Zhang et al. 2012).  
 
When seeded in co-culture with HUVEC, JEG-3 cells grew along the endothelial 
tubes but did not tend to create connections and did not keep the tube formations 
after HUVEC apoptosis. This can be probably explained by an impaired cell-cell 
adhesion due to a deficient expression of adhesion molecules (Bulmer, Burton et al. 
2012).  
 
Studies using this 3D in vitro assay, with additional treatment of serum from normal 
and pathological pregnancies, like preeclampsia, described disrupted tube 
formations of the endothelial cells in co-culture with trophoblasts (Kalkunte, Lai et 
al. 2009). Previous studies in our lab have shown that miR-141 expression, a 
placenta-related miRNA, is higher in plasma and placentas from preeclampsia than 
from normal pregnancies (Ospina-Prieto, Chaiwangyen et al. 2016). Therefore, it 
was aimed to investigate the role of miR-141 in endothelial tube formation during 
the trophoblast-endothelial interaction.  
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5.2. miR-141 
Numerous diseases, of very different etiologies, have been related to the 
dysregulation of miRNAs. miRNAs are short non-coding RNAs (approximately 22 
nucleotides in length), which are involved in the post-transcriptional control of gene 
expression, either by degrading mRNA or by modifying its translation (Gregory and 
Shiekhattar 2005) (Ha and Kim 2014). An increasing number of studies have 
suggested also a link between several miRNAs disorders and pregnancy 
pathologies, such as preeclampsia, and proposed their concentration in 
plasma/serum as potential biomarkers.  
 
The miR-200 family is known for the regulation of cell migration, invasion, and 
proliferation; mostly investigated in the field of cancer research. miRNAs belonging 
to this family have been also identified as endogenous angiogenesis inhibitors. 
Endothelial tube formations decrease significantly when treated with supernatant 
from the ovarian cell line HeyA8, which express miR-200a and miR-200b (Pecot, 
Rupaimoole et al. 2013). miR-141, also part of the miR-200 family, has been 
studied previously in breast, pancreas, ovary and colon malignancies (Humphries 
and Yang 2015).  
 
Overexpression of miR-141, as seen in preeclampsia, was done in HTR8/SVneo 
and JEG-3 cells by transient transfection. The potential effects were analyzed in co-
culture with HUVEC on the tube formation assay. The overexpression of miR-141 in 
transfected HTR8/SVneo cells showed a highly significant (p < 0.001) reduction of 
nodes, suggesting that the overexpression of miR-141 tends to weaken the 
interactions between these cell lines, which ends in tube rupture. In JEG-3 cells the 
endogenous expression of miR-141 is higher than in HTR8/SVneo cells (Ospina-
Prieto, Chaiwangyen et al. 2016), but miR-141 overexpression and inhibition in this 
cell line did lead to almost no changes in its interaction with HUVEC. This can be 
suggested by the fact that the downregulation of miR-141 on JEG-3 cells inhibits 
their proliferation; while, the overexpression of this miRNA does not affect this cell 
process (Morales-Prieto, Schleussner et al. 2011).   
 
The applied model has the capability of mimicking insufficient trophoblast invasion 
followed by reduced tubular formations, which in vivo may lead to poor blood supply 
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as seen during preeclampsia. Results indicate that miR-141 may play a role in the 
angiogenic potential of HTR8/SVneo cells and their communication with endothelial 
cells, probably carried out by EVs.  
 
 
5.3. Extracellular Vesicles  
miRNAs can be released into the extracellular space as a cargo of different types of 
EVs (EXO or MV), protected from RNases and transported in a relatively stable way 
(Ouyang, Mouillet et al. 2014). EVs are considered important carriers of various 
proteins, mRNAs, microRNAs and lipids which interact with distant tissues in the 
body, being involved in the intracellular communication during normal and 
pathological conditions (Raposo and Stoorvogel 2013). Several studies show the 
relationship between mother and embryo during the implantation phase, mediated 
by EVs (Cretoiu, Xu et al. 2016). 
 
Placental miR-141 has been detected in maternal plasma within small particles, 
which cannot be filtered out, even using 0.22 µm filters in contrast to the placental 
chorionic somatomammotropin hormone 1 transcript, a placental mRNA (Chim, 
Shing et al. 2008). To recognize the effect of miR-141-containing EVs, the isolation 
of particles released from transfected trophoblastic cells was done by differential 
centrifugation. Larger vesicles can be separated by consecutive centrifugations at 
increasing speeds, and the small particles (EXO), sedimented at 100,000 x g 
(Colombo, Raposo et al. 2014).  
 
The collected EVs were characterized by NTA and Dot-Blot technique. The NTA 
consist of a laser beam sent through a sample suspension; the light scattered by 
the particles is then directed to a camera attached to a conventional microscope. 
The software identifies and tracks the Brownian motion of each particle from frame 
to frame, enabling the calculation of the approximate diameter and the number of 
particles per ml (Filipe, Hawe et al. 2010). Some results showed that miR-141 may 
be involved in the particle concentration. The EXO-enriched fraction obtained from 
HTR8/SVneo cells transfected with miR-141-mimic showed a slight increase 
compared with its respective controls. Meanwhile, the concentration of MV-enriched 
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fraction was slightly decreased compared with their respective controls. External 
factors are involved in EVs release (Abels and Breakefield 2016); in this case, it can 
be thought that miR-141 may play a role in the production of EVs.   
 
The next characterization step was done by confirmation of membrane proteins with 
a Dot-Blot technique, which is similar to the Western Blot but without electrophoretic 
separation. By using a small amount of each EVs sample, it was showed the 
presence of the tetraspanin CD63 on the EXOs. Together with the CD9, the CD63 
is one of the most common tetraspanins involved in exosome formation. The 
exosomes biogenesis consists in the accumulation of intraluminal vesicles (ILV) 
inside early endosomes which later mature into late endosomes (referred as MVB) 
and subsequently secreted (Colombo, Raposo et al. 2014). These ILV are formed 
by the inward budding of the MVB which contain specific proteins, lipids, and other 
components. 
 
After obtaining information about enriched EXO- and MV-fractions, it was evaluated 
the interaction between HUVEC and EVs. EVs from the plasma of women with 
preeclampsia cause extensive cell membrane damage in primary human coronary 
artery endothelial cells and alter their cellular functions (Cronqvist, Salje et al. 
2014). As the effects seen on HUVEC induced by miR-141-transfected 
HTR8/SVneo cells were stronger than those by miR-141-transfected JEG-3 cells, 
HTR8/SVneo cells were chosen for the further evaluation of EVs effects on tube 
formations. 
 
HUVEC were seeded and cultured until tube formation (4 h), and subsequently, co-
cultured with non-modified HTR8/SVneo cells. The characterized EVs were added 
to the 3D model and after 24 h, tube formations were evaluated through microscopy 
and image analysis. Treatment of non-transfected cells with EVs containing 
elevated miR-141 levels reduced the mean number of nodes at a similar intensity 
as transfection of HTR8/SVneo cells with overexpression of miR-141. But, effects of 
miR-141-containing EXOs were significantly (p < 0.05) higher compared with the 
effects of miR-141-containing MVs.  
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5.4. miR-141 and Preeclampsia: Results Overview 
miRNAs have an involvement in many cellular processes, including angiogenesis. 
Their role on endothelial cells has been assessed by silencing Dicer (an 
endonuclease that cleaves the pre-miRNA into miRNA), using short interfering RNA 
in HUVEC causing an impairment on the development of the tube formations 
(Suarez and Sessa 2009).  
 
The results showed that the overexpression of miR-141 in HTR8/SVneo cells 
diminished the ability to interact with HUVEC, inducing failure of maintenance of 
tube formations and causing an apparent reduction in the trophoblast invasion. This 
result can be related to some effects seen in preeclampsia, such as the inadequate 
remodeling of the uterine spiral arteries.  
 
It can be compared that the results obtained in this work were similar to those 
shown in the patent US 20110059904 A1: Serum-based, diagnostic, biological 
assay to predict pregnancy disorders. This invention provides an assay that 
estimates if a woman is at risk of developing a disorder of pregnancy associated 
with trophoblast invasion (Sharma and Kalkunte 2011). It showed that serum from 
preeclamptic women, either mild or severe, disrupted the characteristic tube 
formations of the cells in co-culture, trophoblasts and endothelial cells (Kalkunte, 
Boij et al. 2010). As shown in Figure 21, the results obtained from the 
overexpression of miR-141 in HTR8/SVneo cells decreased the mean number of 
nodes between tubes, finding out the characteristic tube disruption as seen in 
experiments from Kalkunte et al., when using serum from severe preeclampsia.  
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Figure 21. Comparison between the patent US 20110059904 A1 and results obtained 
with miR-141 overexpression. a) Preeclampsia serum, from both mild and severe 
conditions, disrupted the endothelial-trophoblast interaction (Taken from (Kalkunte, Boij et 
al. 2010). b) A highly significant reduction (*** p < 0.001) of the number of nodes was seen 
upon overexpression of miR-141 in HTR8/SVneo cells (Details on Figure 15). 
 
 
Incorporation of miR-141-containing EVs on non-transfected HTR8/SVneo cells can 
also result in tube disruption, displaying the cell-cell communication through 
particles to nearby cells. Altogether, presented results indicate that miR-141 plays a 
role in the pathogenesis of preeclampsia. 
 
Future experiments will be necessary to further clarify the specific involvement of 
miR-141 in preeclampsia. Those analyses should include the isolation and 
quantification of EVs from human preeclamptic serum, especially in regard to their 
miR-141 concentration, and their effects on the trophoblastic-endothelial interaction 
through the tube formation model. In this way, it could be proved that this miRNA is 
highly responsible for the effects seen in the impaired trophoblast invasion seen in 
the process of preeclampsia.  
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CONCLUSIONS  
 
Preeclampsia is a hypertensive disorder that complicates between 2 - 8% of all 
pregnancies, probably related to improper EVT invasion into uterine spiral arteries 
and further deficient remodeling. During this process, trophoblast cells secrete 
miRNAs within EVs. Their amount and content differ between normal and 
pathological pregnancies, including preeclampsia. miR-141 expression is higher in 
placentas from preeclamptic compared to normal pregnancies. However, the 
function of miRNA-containing EVs on the intercellular communication between 
trophoblast and endothelial cells remains unclear.  
 
In this study, it was explored the function of miR-141 in trophoblast-derived EVs on 
a 3D model for angiogenesis which allows the quantification of trophoblast-
endothelial cell interaction through a specially adapted software. Levels of miR-141 
expression were modified through transient transfection of trophoblastic cells to 
mimic levels as observed in preeclampsia. Analysis of HUVEC tube formation 
alterations was used for comparison between miR-141 overexpressing or inhibited 
HTR8/SVneo and JEG-3 cells, and the effects of their respective EVs.   
 
Overexpression of miR-141 in HTR8/SVneo cells induced altered tube formations, 
an effect not perceived with modified JEG-3 cells. miR-141 containing EVs can be 
uptaken by non-transfected cells resulting also in tube disruption.  Altogether, miR-
141 may be involved in the regulation of the angiogenic potential of trophoblastic 
cells and their communication with endothelial cells through EVs, which may be 
associated with the pathogenesis of preeclampsia.   
 
miR-141 in maternal plasma is detectable from early pregnancy onward and may be 
useful as a potential future diagnostic tool for pregnancy disorders. But further 
verification on clinical samples is needed to be studied before proper application as 
a molecular biomarker. 
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